Sarepta Therapeutics, Inc.

DB:AB3A Stock Report

Market Cap: €3.2b

Sarepta Therapeutics Management

Management criteria checks 3/4

Sarepta Therapeutics' CEO is Doug Ingram, appointed in Jun 2017, has a tenure of 7.92 years. total yearly compensation is $1.98M, comprised of 42.8% salary and 57.2% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth €12.58M. The average tenure of the management team and the board of directors is 4.4 years and 9 years respectively.

Key information

Doug Ingram

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage42.81%
CEO tenure7.9yrs
CEO ownership0.4%
Management average tenure4.4yrs
Board average tenure9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Doug Ingram's remuneration changed compared to Sarepta Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$248m

Dec 31 2024US$2mUS$847k

US$235m

Sep 30 2024n/an/a

US$122m

Jun 30 2024n/an/a

US$47m

Mar 31 2024n/an/a

US$17m

Dec 31 2023US$2mUS$800k

-US$536m

Sep 30 2023n/an/a

-US$691m

Jun 30 2023n/an/a

-US$908m

Mar 31 2023n/an/a

-US$1b

Dec 31 2022US$125mUS$740k

-US$703m

Sep 30 2022n/an/a

-US$716m

Jun 30 2022n/an/a

-US$507m

Mar 31 2022n/an/a

-US$357m

Dec 31 2021US$2mUS$730k

-US$419m

Sep 30 2021n/an/a

-US$486m

Jun 30 2021n/an/a

-US$634m

Mar 31 2021n/an/a

-US$704m

Dec 31 2020US$1mUS$669k

-US$554m

Sep 30 2020n/an/a

-US$601m

Jun 30 2020n/an/a

-US$530m

Mar 31 2020n/an/a

-US$656m

Dec 31 2019US$1mUS$650k

-US$715m

Sep 30 2019n/an/a

-US$620m

Jun 30 2019n/an/a

-US$570m

Mar 31 2019n/an/a

-US$403m

Dec 31 2018US$1mUS$650k

-US$362m

Compensation vs Market: Doug's total compensation ($USD1.98M) is about average for companies of similar size in the German market ($USD2.23M).

Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.

CEO

Doug Ingram (61 yo)

7.9yrs

Tenure

US$1,978,086

Compensation

Mr. Douglas S. Ingram, J.D., Esq., also known as Doug, serves as Independent Director of Arrowhead Pharmaceuticals, Inc. since February 06, 2025. He has been Chief Executive Officer and President of Sarept...

Leadership Team

NamePositionTenureCompensationOwnership
Douglas Ingram
President7.9yrsUS$1.98m0.40%
€ 12.6m
Ian Estepan
Executive VP & CFO4.4yrsUS$2.75m0.046%
€ 1.5m
Bilal Arif
Executive VP & Chief Technical Operations Officer2.4yrsUS$2.54m0.017%
€ 529.3k
Louise Rodino-Klapac
Executive VP4.4yrsUS$2.74m0.059%
€ 1.9m
Dallan Murray
Executive VP & Chief Customer Officer4.4yrsUS$2.67m0.022%
€ 682.6k
Francesca Nolan
Executive Director of Investor Relations and Corporate Communicationsno datano datano data
Cristin Rothfuss
Executive VPless than a yearno datano data
Alison Nasisi
Executive VP & Chief People Officer3.6yrsno datano data
Diane Berry
Executive VP and Chief of Global Policy & Advocacy Officer5.7yrsno datano data
Joseph Bratica
Controller & VP8.2yrsUS$911.89kno data
Mary Jenkins
Senior Manager of Investor Relationsno datano datano data

4.4yrs

Average Tenure

53yo

Average Age

Experienced Management: AB3A's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Douglas Ingram
President7.9yrsUS$1.98m0.40%
€ 12.6m
M. Behrens Wilsey
Independent Chairwoman16.2yrsUS$616.95k0.20%
€ 6.5m
Hans Wigzell
Chairman of Corporate Strategy Board & Independent Non-Employee Director14.9yrsUS$572.02k0.023%
€ 736.1k
Richard Barry
Independent Director9.9yrsUS$593.20k3.24%
€ 102.5m
Beverly Davidson
Member of Strategic & Scientific Advisory Board9.8yrsno datano data
Joy Cavagnaro
Member of Scientific Advisory Board5.5yrsno datano data
Louis Kunkel
Member of Strategic & Scientific Advisory Board9.8yrsno datano data
Claude Nicaise
Independent Non-Employee Director9.9yrsUS$564.64k0.026%
€ 819.4k
Kenneth Fischbeck
Member of Strategic & Scientific Advisory Board8.2yrsno datano data
Carsten Bonnemann
Member of Scientific Advisory Board5.4yrsno datano data
Matthew Wood
Member of Strategic & Scientific Advisory Board8.2yrsno datano data
Annemieke Aartsma-Rus
Member of Scientific Advisory Board5.5yrsno datano data

9.0yrs

Average Tenure

71yo

Average Age

Experienced Board: AB3A's board of directors are considered experienced (9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 08:42
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sarepta Therapeutics, Inc. is covered by 53 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Huidong WangBarclays
Zhiqiang ShuBerenberg